TNF-α-induced depressive-like phenotype and p38MAPK activation are abolished by ascorbic acid treatment

European Neuropsychopharmacology

Volumn 25, Issue 6, 2015, Pages 902-912

  Moretti, Morgana ^a,b   Budni, Josiane ^a   Freitas, Andiara Espíndola ^a   Neis, Vivian Binder ^a   Ribeiro, Camille Mertins ^a   de Oliveira Balen, Grasiela ^a   Rieger, Débora Kurrle ^a   Leal, Rodrigo Bainy ^a   Rodrigues, Ana Lúcia S ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b REGIONAL UNIVERSITY OF BLUMENAU   (Brazil)

Author keywords

Antidepressant; Ascorbic acid; Depression; MAPK; Tail suspension test; TNF

Indexed keywords

7 NITROINDAZOLE; AMFEBUTAMONE; ASCORBIC ACID; DIZOCILPINE; FLUOXETINE; IMIPRAMINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; ANTIOXIDANT; MITOGEN ACTIVATED PROTEIN KINASE 14; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DEPRESSION; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HIPPOCAMPUS; IMMOBILITY; LOCOMOTION; MOUSE; NONHUMAN; OPEN FIELD TEST; PHENOTYPE; POST HOC ANALYSIS; PRIORITY JOURNAL; TAIL SUSPENSION TEST; ANALYSIS OF VARIANCE; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; EXPLORATORY BEHAVIOR; FEMALE; METABOLISM; SIGNAL TRANSDUCTION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIOXIDANTS; ASCORBIC ACID; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; EXPLORATORY BEHAVIOR; FEMALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 14; PHENOTYPE; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84930273545     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.03.006     Document Type: Article

References (51)

1. Amr M., El-Mogy A., Shams T., Vieira K., Lakhan S.E. Efficacy of vitamin C as an adjunct to fluoxetine therapy in pediatric major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. Nutr. J. 2013, 12:31.
2. Bernardini R., Kamilaris T.C., Calogero A.E., Johnson E.O., Gomez M.T., Gold P.W., Chrousos G.P. Interactions between tumor necrosis factor-alpha, hypothalamic corticotropin-releasing hormone, and adrenocorticotropin secretion in the rat. Endocrinology 1990, 126:2876-2881.
3. Binfaré R.W., Rosa A.O., Lobato K.R., Santos A.R.S., Rodrigues A.L.S. Ascorbic acid administration produces an antidepressant-like effect: evidence for the involvement of monoaminergic neurotransmission. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2009, 33:530-540.
4. Brody S. High-dose ascorbic acid increases intercourse frequency and improves mood: a randomized controlled clinical trial. Biol. Psychiatry 2002, 52:371-374.
5. Dunn A.J., Wang J., Ando T. Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Adv. Exp. Med. Biol. 1999, 461:117-127.
6. Elhwuegi A.S. Central monoamines and their role in major depression. Prog Neuro-Psychopharmacol. Biol. Psychiatry 2004, 28:435-451.
7. Esplugues J.V. NO as a signalling molecule in the nervous system. Br. J. Pharmacol. 2002, 135:1079-1095.
8. Fisher B.J., Kraskauskas D., Martin E.J., Farkas D., Wegelin J.A., Brophy D., Ward K.R., Voelkel N.F., Fowler A.A., Natarajan R. Mechanisms of attenuation of abdominal sepsis induced acute lung injury by ascorbic acid. Am. J. Physiol. Lung Cell Mol. Physiol. 2012, 303:L20-32.
9. Galeotti N., Ghelardini C. Selective modulation of the PKCvarepsilon/p38MAP kinase signalling pathway for the antidepressant-like activity of amitriptyline. Neuropharmacology 2012, 62:289-296.
10. Gourley S.L., Wu F.J., Taylor J.R. Corticosterone regulates pERK1/2 map kinase in a chronic depression model. Ann. N Y Acad. Sci. 2008, 1148:509-514.
11. Harkin A.J., Bruce K.H., Craft B., Paul I.A. Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 1. Acute treatments are active in the forced swim test. Eur. J. Pharmacol. 1999, 372:207-213.
12. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res. Rev. 2009, 61:105-123.
13. Hestad K.A., Tonseth S., Stoen C.D., Ueland T., Aukrust P. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J. ECT 2003, 19:183-188.
14. Himmerich H., Fischer J., Bauer K., Kirkby K.C., Sack U., Krugel U. Stress-induced cytokine changes in rats. Eur. Cytokine Netw. 2013.
15. Himmerich H., Fulda S., Linseisen J., Seiler H., Wolfram G., Himmerich S., Gedrich K., Kloiber S., Lucae S., Ising M., Uhr M., Holsboer F., Pollmacher T. Depression, comorbidities and the TNF-alpha system. Eur. Psychiatry 2008, 23:421-429.
16. Janelidze S., Mattei D., Westrin A., Traskman-Bendz L., Brundin L. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav. Immun. 2011, 25:335-339.
17. Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy-from molecular mechanisms to therapeutic benefits. Biochim. Biophys. Acta (BBA) - Proteins Proteomics 2005, 1754:253-262.
18. Kaster M.P., Gadotti V.M., Calixto J.B., Santos A.R., Rodrigues A.L. Depressive-like behavior induced by tumor necrosis factor-alpha in mice. Neuropharmacology 2012, 62:419-426.
19. Kubera M., Basta-Kaim A., Budziszewska B., Rogoz Z., Skuza G., Leskiewicz M., Tetich M., Jaworska-Feil L., Maes M., Lason W. Effect of amantadine and imipramine on immunological parameters of rats subjected to a forced swimming test. Int. J. Neuropsychopharmacol. 2006, 9:297-305.
20. Lanquillon S., Krieg J.C., Bening-Abu-Shach U., Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000, 22:370-379.
21. Li B., Zhang S., Zhang H., Nu W., Cai L., Hertz L., Peng L. Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation. Psychopharmacology (Berl) 2008, 201:443-458.
22. Liu D., Wang Z., Liu S., Wang F., Zhao S., Hao A. Anti-inflammatory effects of fluoxetine in lipopolysaccharide(LPS)-stimulated microglial cells. Neuropharmacology 2011, 61:592-599.
23. Maes M., Meltzer H.Y., Bosmans E., Bergmans R., Vandoolaeghe E., Ranjan R., Desnyder R. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect. Disord. 1995, 34:301-309.
24. Maes M., Verkerk R., Vandoolaeghe E., VanHunsel F., Neels H., Wauters A., Demedts P., Scharpe S. Serotonin-immune interactions in major depression: lower serum tryptophan as a marker of an immune-inflammatory response. Eur. Arch. Psychiatry Clin. Neurosci. 1997, 247:154-161.
25. Majewska M.D., Bell J.A., London E.D. Regulation of the NMDA receptor by redox phenomena: inhibitory role of ascorbate. Brain Res. 1990, 537:328-332.
26. Malynn S., Campos-Torres A., Moynagh P., Haase J. The pro-inflammatory cytokine TNF-alpha regulates the activity and expression of the serotonin transporter (SERT) in astrocytes. Neurochem. Res. 2013, 38:694-704.
27. May J.M., Qu Z.C., Nazarewicz R., Dikalov S. Ascorbic acid efficiently enhances neuronal synthesis of norepinephrine from dopamine. Brain Res. Bull. 2013, 90:35-42.
28. Mikirova N., Casciari J., Rogers A., Taylor P. Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J. Transl. Med. 2012, 10:189.
29. Moretti M., Budni J., Freitas A.E., Rosa P.B., Rodrigues A.L. Antidepressant-like effect of ascorbic acid is associated with the modulation of mammalian target of rapamycin pathway. J. Psychiatr. Res. 2014, 48:16-24.
30. Moretti M., Budni J., Santos D., Antunes A., Daufenbach J., Manosso L., Farina M., Rodrigues A. Protective effects of ascorbic acid on behavior and oxidative status of restraint-stressed mice. J. Mol. Neurosci. 2013, 49:68-79.
31. Moretti M., Colla A., de Oliveira Balen G., dos Santos D.B., Budni J., de Freitas A.E., Farina M., Severo Rodrigues A.L. Ascorbic acid treatment, similarly to fluoxetine, reverses depressive-like behavior and brain oxidative damage induced by chronic unpredictable stress. J. Psychiatric Res. 2012, 46:331-340.
32. Moretti M., Freitas A.E.d., Budni J., Fernandes S.C.P., Balen G.d.O., Rodrigues A.L.S. Involvement of nitric oxide-cGMP pathway in the antidepressant-like effect of ascorbic acid in the tail suspension test. Behav. Brain Res. 2011, 225:328-333.
33. Muller N., Schwarz M.J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol. Psychiatry 2007, 12:988-1000.
34. Neis V.B., Manosso L.M., Moretti M., Freitas A.E., Daufenbach J., Rodrigues A.L. Depressive-like behavior induced by tumor necrosis factor-alpha is abolished by agmatine administration. Behav. Brain Res. 2014, 261:336-344.
35. O'Connor J.C., Lawson M.A., Andre C., Moreau M., Lestage J., Castanon N., Kelley K.W., Dantzer R. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry 2009, 14:511-522.
36. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2008, Academic Press, San Diego. third ed.
37. Pandey G.N., Rizavi H.S., Ren X., Fareed J., Hoppensteadt D.A., Roberts R.C., Conley R.R., Dwivedi Y. Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. J. Psychiatr. Res. 2012, 46:57-63.
38. Peterson G.L. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal. Biochem. 1977, 83:346-356.
39. Qi X., Lin W., Li J., Li H., Wang W., Wang D., Sun M. Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress. Neurobiol. Dis. 2008, 31:278-285.
40. Rebec G.V., Pierce R.C. A vitamin as neuromodulator: ascorbate release into the extracellular fluid of the brain regulates dopaminergic and glutamatergic transmission. Prog. Neurobiol. 1994, 43:537-565.
41. Reichenberg A., Yirmiya R., Schuld A., Kraus T., Haack M., Morag A., Pollmacher T. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry 2001, 58:445-452.
42. Reynolds J.L., Ignatowski T.A., Sud R., Spengler R.N. Brain-derived tumor necrosis factor-alpha and its involvement in noradrenergic neuron functioning involved in the mechanism of action of an antidepressant. J. Pharmacol. Exp. Ther. 2004, 310:1216-1225.
43. Reynolds J.L., Ignatowski T.A., Sud R., Spengler R.N. An antidepressant mechanism of desipramine is to decrease tumor necrosis factor-alpha production culminating in increases in noradrenergic neurotransmission. Neuroscience 2005, 133:519-531.
44. Schiepers O.J., Wichers M.C., Maes M. Cytokines and major depression. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2005, 29:201-217.
45. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985, 85:367-370.
46. Szasz B.K., Mike A., Karoly R., Gerevich Z., Illes P., Vizi E.S., Kiss J.P. Direct inhibitory effect of fluoxetine on N-methyl-D-aspartate receptors in the central nervous system. Biol. Psychiatry 2007, 62:1303-1309.
47. Tao X., Finkbeiner S., Arnold D.B., Shaywitz A.J., Greenberg M.E. Calcium influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 1997, 20:709-726.
48. Udina M., Castellvi P., Moreno-Espana J., Navines R., Valdes M., Forns X., Langohr K., Sola R., Vieta E., Martin-Santos R. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J. Clin. Psychiatry 2012, 73:1128-1138.
49. Wambebe C., Sokomba E. Some behavioural and EEG effects of ascorbic acid in rats. Psychopharmacology (Berl). 1986, 89:167-170.
50. Wong M.L., Licinio J. Research and treatment approaches to depression. Nat. Rev. Neurosci. 2001, 2:343-351.
51. Xu L., Huang Y., Yu X., Yue J., Yang N., Zuo P. The influence of p38 mitogen-activated protein kinase inhibitor on synthesis of inflammatory cytokine tumor necrosis factor alpha in spinal cord of rats with chronic constriction injury. Anesth. Analg. 2007, 105:1838-1844. table of contents.